Research Use Only: What Does the Term Mean?

An intended-use statement

“Research Use Only”, often abbreviated to RUO, is used to communicate that a material is intended for controlled laboratory, analytical or experimental work.

In practical terms, it indicates that the material is not supplied as:

• a licensed medicine;
• a clinical treatment;
• a veterinary treatment;
• a diagnostic product;
• a food;
• a cosmetic;
• a consumer wellness product.

The wording should correspond to the actual way the product is presented, sold and used.

It is not an automatic legal exemption

Adding “Research Use Only” to a label or webpage does not independently determine the product's legal status.

Under Regulation 2 of the Human Medicines Regulations 2012, a medicinal product can be identified through either its presentation or its function.^[1]

The MHRA assesses borderline products case by case and considers the available evidence as a whole.^[2]

Relevant factors may include:

• product name;
• ingredients;
• concentration;
• chemical or pharmacological properties;
• product form;
• labelling;
• packaging;
• instructions;
• website copy;
• linked publications;
• social-media content;
• images;
• testimonials;
• target audience;
• stated and implied uses;
• overall presentation.

A disclaimer cannot neutralise other content that presents or facilitates use of a product as a medicine.

Why website presentation matters

The MHRA states that internet information about a product and its uses may be treated as advertising evidence.

It may consider:

• direct medicinal claims;
• implied medicinal claims;
• references to medical conditions;
• references to clinical research;
• editorial medicinal content;
• comparisons with licensed medicines;
• recommendations by health professionals;
• testimonials implying treatment;
• medical graphics;
• linked publications;
• linked external webpages;
• product form and method of use.

This means a retailer cannot safely place clinical treatment information beside a purchase button and rely on an RUO disclaimer to change the overall impression.

The message conveyed by the complete presentation matters more than one isolated phrase.

What genuine laboratory-only positioning looks like

A genuine research-only presentation should remain focused on information relevant to laboratory procurement and analytical work, such as:

• chemical or material identity;
• catalogue number;
• batch number;
• stated quantity;
• physical form;
• analytical specification;
• Certificate of Analysis;
• test methods;
• storage statement;
• safety documentation;
• traceability;
• laboratory handling controls.

It should not contain information that encourages self-administration or veterinary administration.

What RUO material must not be promoted for

Research-only material must not be promoted or supplied with instructions for:

• treating or preventing disease;
• changing body weight;
• changing appearance through a pharmacological action;
• correcting a physiological function;
• human dosing;
• veterinary dosing;
• injection;
• oral consumption;
• self-experimentation;
• diagnosis;
• clinical treatment.

It should not be accompanied by:

• dosage calculators;
• administration schedules;
• reconstitution-for-injection instructions;
• patient testimonials;
• before-and-after images;
• therapeutic protocols;
• claims of safety or effectiveness;
• comparisons with authorised medicines;
• clinician endorsements;
• disease-specific purchasing advice.

Research use is not clinical-trial use

Laboratory research material should not be confused with an investigational medicinal product used in an authorised clinical trial.

Clinical trials require a regulated framework covering areas such as:

• ethics approval;
• regulatory authorisation;
• product quality;
• manufacturing controls;
• participant consent;
• safety monitoring;
• protocol governance;
• qualified investigators.

A commercial RUO label does not create that framework.

Responsibilities of the purchaser

Purchasers are responsible for ensuring that:

• their intended work is lawful;
• the material is suitable for the experiment;
• appropriate risk assessment has been completed;
• trained personnel handle the material;
• storage and access are controlled;
• suitable personal protective equipment is used;
• applicable safety documentation is reviewed;
• waste is disposed of appropriately;
• the material is not administered to humans or animals;
• applicable institutional and regulatory requirements are followed.

Marketing requirements

The CAP Code states that medicines require appropriate authorisation before being marketed and that marketing for an unlicensed product must not make a medicinal or therapeutic claim or refer to an ailment unless authorised by the MHRA.^[3]

Because classification is fact-specific, businesses selling borderline materials should obtain specialist UK regulatory advice or contact the MHRA Borderlines Section where uncertainty remains.